Wellington Management Group LLP Sells 153,294 Shares of Inspire Medical Systems, Inc. $INSP

Wellington Management Group LLP trimmed its position in Inspire Medical Systems, Inc. (NYSE:INSP) by 6.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 2,382,660 shares of the company’s stock after selling 153,294 shares during the period. Wellington Management Group LLP owned about 8.24% of Inspire Medical Systems worth $106,290,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Royal Bank of Canada increased its position in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after acquiring an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Inspire Medical Systems in the 1st quarter valued at $524,000. Goldman Sachs Group Inc. boosted its holdings in shares of Inspire Medical Systems by 57.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after buying an additional 18,857 shares during the last quarter. Marshall Wace LLP grew its position in Inspire Medical Systems by 3.8% during the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after buying an additional 577 shares during the period. Finally, Jump Financial LLC purchased a new stake in Inspire Medical Systems during the second quarter worth about $931,000. Institutional investors own 94.91% of the company’s stock.

Insiders Place Their Bets

In related news, insider Jason P. Kelly sold 963 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the sale, the insider directly owned 18,985 shares of the company’s stock, valued at $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 2.20% of the stock is owned by corporate insiders.

Inspire Medical Systems Stock Performance

NYSE:INSP opened at $61.67 on Wednesday. Inspire Medical Systems, Inc. has a 52-week low of $38.91 and a 52-week high of $147.03. The stock has a fifty day moving average of $53.93 and a 200 day moving average of $52.32. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of 13.35, a P/E/G ratio of 4.79 and a beta of 0.70.

Inspire Medical Systems (NYSE:INSP) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.38. The firm had revenue of $200.58 million for the quarter, compared to analysts’ expectations of $194.72 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company’s revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities analysts forecast that Inspire Medical Systems, Inc. will post 1.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INSP has been the topic of a number of research analyst reports. UBS Group began coverage on shares of Inspire Medical Systems in a research note on Tuesday, July 28th. They issued a “sell” rating and a $39.00 target price on the stock. Piper Sandler raised their target price on Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Robert W. Baird boosted their target price on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Freedom Capital upgraded Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. Finally, JPMorgan Chase & Co. boosted their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $66.19.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.